Journal of Clinical OncologyFuzuloparib Maintenance Therapy in Patients with Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial

This phase III trial evaluated the PARP inhibitor fuzuloparib versus placebo as a maintenance treatment after second- or later-line platinum-based chemotherapy in patients with high-grade, platinum-sensitive, recurrent ovarian cancer. Two-hundred-fifty-two (252) patients were randomly assigned to the fuzuloparib (n = 167) or placebo (n = 85). Twice daily oral fuzuloparib as maintenance therapy was superior to placebo in PFS improvement. Further, benefit was observed both in patients with germline BRCA 1/2 mutations and in those without mutations.